Planned omalizumab discontinuation in CSU management as a sustainable strategy: A 2-year real-life study

被引：3
|
作者：
Di Bona, Danilo [1 ]
Nettis, Eustachio [1 ]
Minenna, Elena [2 ]
Lovecchio, Antonella [1 ]
Paolino, Donato [1 ]
Cristina Nizi, Maria [3 ]
Albanesi, Marcello [1 ]
Ridolo, Erminia [3 ]
Filomena Caiaffa, Maria [2 ]
Macchia, Luigi [1 ]
机构：
[1] Univ Bari Aldo Moro, Dept Emergency & Organ Transplantat, Sch & Chair Allergol & Clin Immunol, Piazza Giulio Cesare 11, I-70124 Bari, Italy
[2] Univ Foggia, Dept Med & Surg Sci, Foggia, Italy
[3] Univ Parma, Med & Surg Dept, Allergy & Clin Immunol, Parma, Italy
来源：
ALLERGY | 2020年 / 75卷 / 10期
关键词：
URTICARIA;
D O I：
10.1111/all.14341
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：2681 / 2684
页数：4
相关论文
共 50 条
  • [31] Omalizumab Gets Tolerance In Patients With Severe Food Allergy: A Real-Life Study
    Arasi, Stefania
    Artesani, Maria C.
    Riccardi, Carla
    Mennini, Maurizio
    Pecora, Valentina
    Fierro, Vincenzo
    Calandrelli, Veronica
    Dahdah, Lamia
    Valluzzi, Rocco
    Fiocchi, Alessandro G.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2019, 143 (02) : AB271 - AB271
  • [32] Effectiveness of Omalizumab in Severe Allergic Asthma and Nasal Polyposis: A Real-Life Study
    Tiotiu, A.
    Oster, J. P.
    Roux, P. R.
    Nguyen Thi, P. L.
    Peiffer, G.
    Bonniaud, P.
    Daiphin, J. C.
    de Blay, F.
    JOURNAL OF INVESTIGATIONAL ALLERGOLOGY AND CLINICAL IMMUNOLOGY, 2020, 30 (01) : 49 - 57
  • [33] Real-life assessment of erenumab discontinuation following one year of treatment in migraine patients
    Matteo, Eleonora
    Mascarella, Davide
    Pensato, Umberto
    Turrini, Agnese
    Favoni, Valentina
    Pierangeli, Giulia
    Cortelli, Pietro
    Cevoli, Sabina
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2021, 429 : 216 - 216
  • [34] Four-week total IgE/baseline total IgE ratio - Biomarker for omalizumab good response in CSU real-life patients
    Caldeira, L. Esteves
    Bernardino, A.
    Paulino, M.
    Costa, C.
    ALLERGY, 2023, 78
  • [35] Long-Term Omalizumab Treatment: A Multicenter, Real-Life, 5-Year Trial
    Yorgancioglu, Arzu
    Erkekol, Ferda Oner
    Mungan, Dilsad
    Erdinc, Munevver
    Gemicioglu, Bilun
    Ozseker, Zeynep Ferhan
    Degirmenci, Papatya Bayrak
    Nayci, Sibel
    Cilli, Aykut
    Erdenen, Fusun
    Kirmaz, Cengiz
    Ediger, Dane
    Yalcin, Arzu Didem
    Buyukozturk, Suna
    Ozturk, Sami
    Gulec, Mustafa
    Isik, Sacide Rana
    Kalyoncu, Ali Fuat
    Goksel, Ozlem
    Aydin, Omur
    Havlucu, Yavuz
    Ar, Idilhan Baloglu
    Erdogdu, Ahmet
    INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, 2018, 176 (3-4) : 225 - 233
  • [36] Long-term "real-life" safety of omalizumab in patients with severe uncontrolled asthma: A nine-year study
    Di Bona, Danilo
    Fiorino, Irene
    Taurino, Marialuisa
    Frisenda, Flavia
    Minenna, Elena
    Pasculli, Carlo
    Kourtis, Georgios
    Rucco, Anna Simona
    Nico, Andrea
    Albanesi, Marcello
    Giliberti, Lucia
    D'Elia, Luciana
    Caiaffa, Maria Filomena
    Macchia, Luigi
    RESPIRATORY MEDICINE, 2017, 130 : 55 - 60
  • [37] Long-term evaluation of response to omalizumab therapy in real life by a novel multimodular approach The Real-life Effectiveness of Omalizumab Therapy (REALITY) study
    Singh, Harjinder
    Peters, Jay, I
    Kaur, Yogeet
    Maselli, Diego J.
    Diaz, Joseph D.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2019, 123 (05) : 476 - +
  • [38] Real-life study of patients treated with omalizumab in chronic spontaneous urticaria in France: One-year final results of LUCIOL study
    Barbaud, A.
    Staumont-Salle, D.
    Bouillet, L.
    Vicaut, E.
    Tetart, F.
    Azib-Meftah, S.
    Milpied, B.
    Fougerousse, A.
    Benjamin, K.
    Cartiaux, H.
    Lamirand, A.
    Bruno, N.
    Berard, F.
    ALLERGY, 2020, 75 : 319 - 320
  • [39] Predictive factors of recurrence after omalizumab cessation in the elderly with urticaria: A real-life study
    Oztop, Nida
    Demir, Semra
    Unal, Derya
    Beyaz, Sengul
    Terzioglu, Kadriye
    Olgac, Muge
    Gelincik, Asli
    ALLERGY AND ASTHMA PROCEEDINGS, 2022, 43 (06) : 519 - 528
  • [40] "Real-life" effectiveness of omalizumab in patients with severe persistent allergic asthma: The PERSIST study
    Brusselle, G.
    Michils, A.
    Louis, R.
    Dupont, L.
    de Maele, B. Van
    Delobbe, A.
    Pilette, C.
    Lee, C. S.
    Gurdain, S.
    Vancayzeele, S.
    Lecomte, P.
    Hermans, C.
    MacDonald, K.
    Song, M.
    Abraham, I.
    RESPIRATORY MEDICINE, 2009, 103 (11) : 1633 - 1642
12345